NYSE$BLCO
Bausch + Lomb Corp · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Headline financials
Revenue & EPS history
Bausch + Lomb · Revenue · Quarterly
$949M
Q3 2021+3.6%vs Q3 2020
Revenue by segment
Bausch + Lomb · $899M total across 3 segments · Q3 2021
- Vision Care$605M—67.3%
- Surgical$173M—19.2%
- Pharmaceuticals$121M—13.5%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2021
-1.0%
Avg return
Earnings day
-1.8%
Avg return
5 days after
-1.0%
Avg return
30 days after
43%
9 / 21 earnings
Positive
+18.7%
Q4 2023
Best reaction
-15.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.8% | +2.9% | -1.0% | |
| Q4 2025 | +0.2% | +1.5% | -11.3% | |
| Q3 2025 | +2.1% | +0.3% | +6.5% | |
| Q1 2025 | -15.7% | -17.1% | -16.4% | |
| Q4 2024 | -0.3% | -3.3% | -4.8% | |
| Q3 2024 | -2.3% | -4.3% | -4.5% | |
| Q2 2024 | -0.1% | -8.7% | -2.6% | |
| Q1 2024 | -4.7% | -0.7% | +5.5% | |
| Q4 2023 | +18.7% | +15.7% | +10.8% | |
| Q3 2023 | +4.6% | +2.9% | -4.3% | |
| Q2 2023 | -2.5% | -3.4% | -7.2% | |
| Q1 2023 | +0.1% | +4.6% | +4.4% | |
| Q4 2020 | +0.4% | -3.7% | -14.1% | |
| Q4 2022 | +0.4% | -3.7% | -14.1% | |
| Q3 2022 | -4.9% | +5.6% | +7.9% | |
| Q3 2021 | -4.9% | +5.6% | +7.9% | |
| Q2 2022 | +4.7% | +6.3% | +1.2% | |
| Q2 2021 | +4.7% | +6.3% | +1.2% | |
| Q1 2022 | -6.8% | -14.6% | +5.0% | |
| Q4 2021 | -6.8% | -14.6% | +5.0% | |
| Q1 2021 | -6.8% | -14.6% | +5.0% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro